Release testing can be a critical bottleneck in advanced therapy manufacturing. We're addressing this by making analytics a more integrated part of manufacturing, leading to faster, actionable data while maintaining analytical standards for GMP. bit.ly/4y5650Y

What if protein engineering could make a gene insertion protein 3.4x more active? Using machine learning, #ElevateBio engineered a more active protein in just 2 rounds over 4 wks. What was the model trained on, and why does it matter? Read the blog: bit.ly/47AryUJ

The @alliancerm’s new playbook explores how platform-based approaches can streamline drug development & bring life-changing therapies to those in need. We’d like to recognize the contributions of April Sena, Ph.D. and Allie Crawley to this important publication. ⬇️

CFO Bhakti Bhargava will present at the Goodwin Pharma Services Symposium. The session will explore manufacturing, supply chain, operational excellence, and growth across CDMOs, CROs, and pharma services platforms. We look forward to connecting with leaders in the pharma space.

Katie Shannon, VP, Site Head, ElevateBio Pittsburgh will join a cross-company panel featuring experts from @SartoriusGlobal, Invert Bio, & @thermofisher to discuss why autologous cell therapies are so expensive to scale. Register: bit.ly/4hpeveT

98% batch success across #celltherapy, #viralvector, and #mRNA programs. That number is not a quality metric. It is a system outcome. Reliability gets engineered in before a single cell is ever touched. Read more: bit.ly/4yVbzNd

A new whitepaper shows how multi-domain protein engineering manages the tradeoff, with data on PAM re-programming at ~90% efficiency, ABE specificity engineering, and de novo enzyme design. Read the whitepaper: bit.ly/4jzsGiE

Not every genetic disease requires rewriting DNA. #ElevateBio’s epigenetic editing platform repressed B2M expression for 4+ wks after single transient mRNA delivery in Jurkat cells w/o permanent sequence change or continuous dosing. bit.ly/3TO6kQb

Sterility testing can take 14 days. Manufacturing 7-10. For patients waiting on a CAR-T infusion, that math matters. #ElevateBio scientists are working toward a 4-5 day assay that detects bacteria, fungi & mycoplasma at 10 CFU. 🎥 Watch the recording: bit.ly/4hKav7q

Find us at @alliancerm’s 2026 Cell & Gene Meeting on the Mesa where CEO Chris Murphy will spotlight our integrated platform for addressing scale & cost challenges, and highlight our expanding Pittsburgh footprint. CTO Michael Paglia will speak on a panel on process improvement.

We recently entered into a commercial manufacturing and supply agreement with @Kyverna_Tx. This milestone reflects the great work of our team, who has doubled the number of GMP batches at ElevateBio this year while maintaining a 98%+ batch success rate. bit.ly/3Svimxc

In autologous cell therapy, labor and facility time comprise 50–70% of COGs. Both are locked in by decisions made during process development. Chris Shumway, Sr. Director of Manufacturing, explains why COGs is a process design problem. Read more: bit.ly/4y53XHw

Dr. Allie Crawley outlines how and why ElevateBio engages in orthogonal detection methods to de-risk therapies prior to regulatory submission. Read the article and view Dr. Crawley’s presentation here: bit.ly/4yKcEXG

ElevateBio CTO, Mike Paglia, will participate in a panel discussion at the BioInnovation Group (BIG) Executive Summit during Biotech Week Boston. Learn more: bit.ly/4ynJ8XE

Adriana Geldart, Ph.D., Michael Giffin,Ph.D., and Will Arnold, Ph.D., will represent ElevateBio in a Fierce Biotech webinar to discuss leveraging next-generation sequencing (NGS) to transform product release. Learn more: bit.ly/3Va5P37

Making critical gene editing decisions is often complex. We provide a clear, streamlined path to the answers your program needs through our three partnership models. Discover the best fit for your program: bit.ly/3Uh5AD1

Uzair Beg will moderate a Q+A between Courtney Keiser and Chris Shumway at the 11th Annual CAR-TCR Summit to discuss how to operationalize manufacturing at scale without compromising quality. Email [email protected] to book meetings with us during the conference.

At the 11th CAR-TCR Summit on 9/17, our teammate Chesney Michels and Pierre Springuel from @SartoriusGlobal will lead a conversation around unlocking the industrialization of cell therapy production, exploring data generated using Eveo®, Sartorius’s closed cell therapy platform.